Company news
Brightgene Bio-medical Technology Co. Ltd. Class A (SSE:688166) news
Brightgene Bio-medical Technology Co. Ltd. Class A news releases on 6ix. Latest, Nov 22, 2025: Announcement on Convening the Q3 2025 Performance Briefing
Press releases — page 2
Announcement on Convening the Q3 2025 Performance Briefing
November 21, 2025
Announcement on Waiver of the Preemptive Right for Capital Increase and Stock Expansion of Joint-stock Company and Related Party Transactions
November 14, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BGM1812 Injection
November 13, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
October 30, 2025
Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement
October 28, 2025
Announcement on Receipt of SSE’s "Decision to Terminate the Review of the Private Placement Stock Issuance Application by BrightGene Bio-Medical Technology Co., Ltd."
October 20, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 17, 2025
Announcement on Resolutions of the 11th Meeting of the 4th Board of Supervisors
October 15, 2025
Announcement on Conversion Result of Convertible Bonds and Share Changes
October 9, 2025
Announcement on Voluntary Disclosure of BGM1812 Injection Obtaining US. FDA Approval for Drug Clinical Trial
September 29, 2025
Announcement on Increasing of Independent Directors of the 4th Board of Directors and Adjustment of Members of Special Committees of the Board of Directors
September 26, 2025
Announcement on the Chairman's Proposal to Repurchase Shares
September 25, 2025
Announcement on Serious Abnormal Fluctuations in Stock Trading
September 24, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of BGM0504 Tablets
September 15, 2025
Announcement on Not Redeeming "BrightGene Convertible Bonds" in Advance
September 11, 2025
Indicative Announcement on "Brightgene Convertible Bonds" Expected to Meet Conditions for Redemption
September 5, 2025
Report on Use of Previously Raised Funds (2nd Revised Edition)
August 28, 2025
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
June 23, 2025